{"protocolSection": {"identificationModule": {"nctId": "NCT02980133", "orgStudyIdInfo": {"id": "FSS-AS-30003"}, "secondaryIdInfos": [{"id": "2016-003835-39", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler", "officialTitle": "A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2021-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-12-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-04-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-04-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-11-30", "studyFirstSubmitQcDate": "2016-11-30", "studyFirstPostDateStruct": {"date": "2016-12-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-03-05", "resultsFirstSubmitQcDate": "2020-03-05", "resultsFirstPostDateStruct": {"date": "2020-03-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-11-05", "lastUpdatePostDateStruct": {"date": "2021-11-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study is to evaluate the safety and efficacy of fluticasone propionate and fluticasone propionate salmeterol in pediatric participants with a documented history of persistent asthma."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 841, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo MDPI", "type": "PLACEBO_COMPARATOR", "description": "Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.", "interventionNames": ["Drug: Placebo MDPI"]}, {"label": "Fp MDPI 25 mcg BID", "type": "EXPERIMENTAL", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.", "interventionNames": ["Drug: Fluticasone Propionate"]}, {"label": "Fp MDPI 50 mcg BID", "type": "EXPERIMENTAL", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.", "interventionNames": ["Drug: Fluticasone Propionate"]}, {"label": "FS MDPI 50/12.5 mcg BID", "type": "EXPERIMENTAL", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.", "interventionNames": ["Drug: Fluticasone Propionate/Salmeterol"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone Propionate", "description": "Fluticasone propionate was administered via MDPI per the dose and schedule specified in the arm.", "armGroupLabels": ["Fp MDPI 25 mcg BID", "Fp MDPI 50 mcg BID"]}, {"type": "DRUG", "name": "Fluticasone Propionate/Salmeterol", "description": "Fluticasone propionate/salmeterol was administered via MDPI per the dose and schedule specified in the arm.", "armGroupLabels": ["FS MDPI 50/12.5 mcg BID"]}, {"type": "DRUG", "name": "Placebo MDPI", "description": "Matching placebo was administered via MDPI per the schedule specified in the arm.", "armGroupLabels": ["Placebo MDPI"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. The baseline 1-hour trough morning percent predicted FEV1 was defined as the predose trough morning percent predicted FEV1 measurement at the randomization visit (Baseline \\[Day 1\\]) at the investigational center. The IMP dose was administered right after the predose FEV1 measurement (within a 10 minute window). Participant then performed 1-hour (\u00b110 minutes) postdose lung function assessments on Week 12 at the investigational center.", "timeFrame": "Baseline, Week 12"}, {"measure": "For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Baseline trough morning percent predicted FEV1 was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \\[Day 1\\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \\[Day 1\\]). For postdose weekly average of trough morning percent predicted FEV1 measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning FEV1 values divided by the number of nonmissing assessments.", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Morning PEF was determined in the morning, before administration of IMP or rescue medications. Baseline trough morning PEF was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \\[Day 1\\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \\[Day 1\\]). For postdose weekly average of trough morning PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning PEF values divided by the number of nonmissing assessments.", "timeFrame": "Baseline, Week 1 to 12"}, {"measure": "Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12", "description": "Participants recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each morning and evening in the electronic patient diary. An entry of 0 inhalations indicated no rescue medication was needed. To calculate the total daily use of albuterol/salbutamol inhalation aerosol (number of inhalations), the electronic patient diary entry on randomization visit (Baseline \\[Day 1\\]) was defined as the first day of analysis. The weekly average of the total daily inhalations was the average based on the available data for that week. The average was calculated as the sum of total daily inhalations over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and standard error (SE) were obtained using mixed model for repeated measures (MMRM).", "timeFrame": "Baseline, Week 1 to 12"}, {"measure": "Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12", "description": "Asthma symptom scores were recorded in the patient diary. Each participant assessed the symptoms of cough, wheeze, shortness of breath, and chest tightness and entered a single score that was inclusive of all symptoms. Daytime Symptom Score (determined in the evening) ranged from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. Nighttime Symptom Score (determined in the morning) ranged from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score was the average of the daytime and nighttime scores. The total daily asthma symptom score ranged from 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night. The weekly average was calculated as the sum of total daily asthma symptom scores over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and SE were obtained using MMRM.", "timeFrame": "Baseline, Week 1 to 12"}, {"measure": "Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period", "description": "C-ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The first 4 items of the test were completed by the participant, while the last 3 items were completed by the participant's parents/legal guardians/caregivers. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranging from 0 to 27. These scores spanned the continuum of poor control of asthma (score \u22645) to complete control of asthma (score \u226525), with a cut off score of 19 indicating participants with poorly controlled asthma. LS mean and SE were obtained using MMRM.", "timeFrame": "Baseline, Week 1 to 12"}, {"measure": "Time to First Onset of Effect", "description": "The time to first onset of effect, defined as the first decrease from baseline in daily rescue medication use, was calculated based on the number of inhalations of rescue medication (albuterol/salbutamol hydrofluoroalkane metered-dose inhaler \\[HFA MDI\\] \\[90 mcg ex actuator\\] or equivalent) recorded by the participant each morning and evening in the patient diary built into the handheld device.", "timeFrame": "Baseline up to Week 12"}, {"measure": "Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period", "timeFrame": "Baseline up to Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* The participant has a diagnosis of asthma as defined by the National Institutes of Health (NIH).\n* The participant has persistent asthma with a FEV1 \u226550% and \u226490% of the value predicted for age, height, sex, and race at the screening visit (SV).\n* The participant's persistent asthma is stable and is currently being treated with stable asthma therapy for at least 30 days before the SV. Participants currently on a short-acting \u03b22-agonist (SABA) only, regimen or as needed (PRN), are not eligible.\n* The participant has demonstrated \u226510% response to a bronchodilator from screening FEV1 within 30 minutes after 2 to 4 inhalations of albuterol/salbutamol.\n* The participant (with assistance from parents/legal guardians/caregivers, as needed) is able to perform technically acceptable lung function assessments by handheld device.\n* All participants must be able to replace their current SABA with albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) inhalation aerosol at the SV for use as needed for the duration of the study.\n\n  * Additional criteria apply, please contact the investigator for more information\n\nExclusion Criteria:\n\n* The participant has a history of life-threatening asthma exacerbation that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures.\n* The participant is pregnant or lactating or plans to become pregnant during the study period or within 30 days after the participant's last study-related visit.\n* The participant has a known hypersensitivity to any corticosteroid, salmeterol, or any of the excipients in the investigational medicinal product (IMP) or rescue medication formulation (that is, lactose).\n* The participant has been treated with any known strong cytochrome P450 (CYP) 3A4 inhibitors (for example, ketoconazole, ritonavir, clarithromycin) within 30 days before the SV or plans to be treated with any strong CYP3A4 inhibitor during the study.\n* The participant currently smokes or has a smoking history. The participant must not have used tobacco products within the past year (for example, cigarettes, cigars, chewing tobacco, or pipe tobacco).\n* The participant has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV or has had any hospitalization for asthma within 2 months before the SV.\n* The participant has used immunosuppressive medications within 30 days before the SV.\n* The participant has untreated oral candidiasis at the SV. Participants with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the run-in period.\n* The participant has a history of a positive test for human immunodeficiency virus, active hepatitis B virus, or hepatitis C infection.\n* The participant is an immediate relative of an employee of the clinical investigational center.\n* A member of the participant's household is participating in the study at the same time.\n* Vulnerable participants (that is, people kept in detention) are excluded from participation.\n\n  * Additional criteria apply, please contact the investigator for more information", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Teva Medical Expert, MD", "affiliation": "Teva Branded Pharmaceutical Products R&D, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Teva Investigational Site 13881", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Teva Investigational Site 13883", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Teva Investigational Site 13906", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Teva Investigational Site 14615", "city": "Corona", "state": "California", "zip": "92883", "country": "United States", "geoPoint": {"lat": 33.87529, "lon": -117.56644}}, {"facility": "Teva Investigational Site 13892", "city": "Downey", "state": "California", "zip": "90241", "country": "United States", "geoPoint": {"lat": 33.94001, "lon": -118.13257}}, {"facility": "Teva Investigational Site 13875", "city": "Fountain Valley", "state": "California", "zip": "92708", "country": "United States", "geoPoint": {"lat": 33.70918, "lon": -117.95367}}, {"facility": "Teva Investigational Site 13904", "city": "Huntington Beach", "state": "California", "zip": "92647 6818", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Investigational Site 13877", "city": "Huntington Beach", "state": "California", "zip": "92648", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Teva Investigational Site 14668", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Teva Investigational Site 13914", "city": "Napa", "state": "California", "zip": "94558", "country": "United States", "geoPoint": {"lat": 38.29714, "lon": -122.28553}}, {"facility": "Teva Investigational Site 13918", "city": "Paramount", "state": "California", "zip": "90723", "country": "United States", "geoPoint": {"lat": 33.88946, "lon": -118.15979}}, {"facility": "Teva Investigational Site 14618", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Teva Investigational Site 13912", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "Teva Investigational Site 13847", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Teva Investigational Site 13848", "city": "Thousand Oaks", "state": "California", "zip": "91360", "country": "United States", "geoPoint": {"lat": 34.17056, "lon": -118.83759}}, {"facility": "Teva Investigational Site 13856", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Teva Investigational Site 13910", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Teva Investigational Site 13868", "city": "Longmont", "state": "Colorado", "zip": "80501", "country": "United States", "geoPoint": {"lat": 40.16721, "lon": -105.10193}}, {"facility": "Teva Investigational Site 13913", "city": "Chiefland", "state": "Florida", "zip": "32626", "country": "United States", "geoPoint": {"lat": 29.47496, "lon": -82.85984}}, {"facility": "Teva Investigational Site 14616", "city": "DeLand", "state": "Florida", "zip": "32720", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"facility": "Teva Investigational Site 13909", "city": "Homestead", "state": "Florida", "zip": "33030", "country": "United States", "geoPoint": {"lat": 25.46872, "lon": -80.47756}}, {"facility": "Teva Investigational Site 13857", "city": "Loxahatchee Groves", "state": "Florida", "zip": "33470", "country": "United States", "geoPoint": {"lat": 26.68368, "lon": -80.27977}}, {"facility": "Teva Investigational Site 13870", "city": "Miami Lakes", "state": "Florida", "zip": "33014", "country": "United States", "geoPoint": {"lat": 25.90871, "lon": -80.30866}}, {"facility": "Teva Investigational Site 14617", "city": "Miami Lakes", "state": "Florida", "zip": "33015", "country": "United States", "geoPoint": {"lat": 25.90871, "lon": -80.30866}}, {"facility": "Teva Investigational Site 13916", "city": "Miami Springs", "state": "Florida", "zip": "33185", "country": "United States", "geoPoint": {"lat": 25.82232, "lon": -80.2895}}, {"facility": "Teva Investigational Site 13872", "city": "Miami", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 13907", "city": "Miami", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 13893", "city": "Miami", "state": "Florida", "zip": "33142", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 13886", "city": "Miami", "state": "Florida", "zip": "33155", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 13899", "city": "Miami", "state": "Florida", "zip": "33175", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 13864", "city": "Miami", "state": "Florida", "zip": "33176", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 13880", "city": "Miami", "state": "Florida", "zip": "33176", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Teva Investigational Site 13911", "city": "Ocala", "state": "Florida", "zip": "34471", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "Teva Investigational Site 13876", "city": "Palmetto Bay", "state": "Florida", "zip": "33157", "country": "United States", "geoPoint": {"lat": 25.62177, "lon": -80.32477}}, {"facility": "Teva Investigational Site 13844", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Teva Investigational Site 13866", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Teva Investigational Site 13858", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Teva Investigational Site 13896", "city": "Eagle", "state": "Idaho", "zip": "83616", "country": "United States", "geoPoint": {"lat": 43.69544, "lon": -116.35401}}, {"facility": "Teva Investigational Site 13903", "city": "Idaho Falls", "state": "Idaho", "zip": "83402", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "Teva Investigational Site 13882", "city": "Springfield", "state": "Illinois", "zip": "62704", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "Teva Investigational Site 13887", "city": "Overland Park", "state": "Kansas", "zip": "66210", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Teva Investigational Site 13851", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Teva Investigational Site 13849", "city": "Rockville", "state": "Maryland", "zip": "20850", "country": "United States", "geoPoint": {"lat": 39.084, "lon": -77.15276}}, {"facility": "Teva Investigational Site 13865", "city": "Columbia", "state": "Missouri", "zip": "65203", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "Teva Investigational Site 13885", "city": "Columbia", "state": "Missouri", "zip": "65203", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "Teva Investigational Site 13891", "city": "Missoula", "state": "Montana", "zip": "59808", "country": "United States", "geoPoint": {"lat": 46.87215, "lon": -113.994}}, {"facility": "Teva Investigational Site 13897", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Teva Investigational Site 13854", "city": "Verona", "state": "New Jersey", "zip": "07044", "country": "United States", "geoPoint": {"lat": 40.82982, "lon": -74.24015}}, {"facility": "Teva Investigational Site 13908", "city": "Watertown", "state": "New York", "zip": "13601", "country": "United States", "geoPoint": {"lat": 43.97478, "lon": -75.91076}}, {"facility": "Teva Investigational Site 13890", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Teva Investigational Site 13863", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Teva Investigational Site 13855", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Teva Investigational Site 13905", "city": "Milford", "state": "Ohio", "zip": "45150", "country": "United States", "geoPoint": {"lat": 39.17534, "lon": -84.29438}}, {"facility": "Teva Investigational Site 13852", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 13879", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 13884", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Teva Investigational Site 13860", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Teva Investigational Site 13894", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Teva Investigational Site 13861", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Teva Investigational Site 13874", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Teva Investigational Site 13895", "city": "Scottdale", "state": "Pennsylvania", "zip": "15683", "country": "United States", "geoPoint": {"lat": 40.10035, "lon": -79.58698}}, {"facility": "Teva Investigational Site 13888", "city": "Providence", "state": "Rhode Island", "zip": "02909", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Teva Investigational Site 13871", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Teva Investigational Site 13889", "city": "Charleston", "state": "South Carolina", "zip": "29414", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Teva Investigational Site 13853", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Teva Investigational Site 14671", "city": "Summerville", "state": "South Carolina", "zip": "29483", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "Teva Investigational Site 13898", "city": "Baytown", "state": "Texas", "zip": "77521", "country": "United States", "geoPoint": {"lat": 29.7355, "lon": -94.97743}}, {"facility": "Teva Investigational Site 14673", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Teva Investigational Site 13867", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Teva Investigational Site 13902", "city": "Killeen", "state": "Texas", "zip": "76542-0969", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "Teva Investigational Site 13846", "city": "Live Oak", "state": "Texas", "zip": "78233", "country": "United States", "geoPoint": {"lat": 29.56523, "lon": -98.3364}}, {"facility": "Teva Investigational Site 13878", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 14672", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 13917", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Teva Investigational Site 13845", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Teva Investigational Site 13850", "city": "Richmond", "state": "Virginia", "zip": "23223", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Teva Investigational Site 13915", "city": "Bellingham", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}, {"facility": "Teva Investigational Site 81041", "city": "Kutaisi", "zip": "4600", "country": "Georgia", "geoPoint": {"lat": 42.26791, "lon": 42.69459}}, {"facility": "Teva Investigational Site 81047", "city": "Tbilisi", "zip": "0119", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Teva Investigational Site 81046", "city": "Tbilisi", "zip": "0141", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Teva Investigational Site 81044", "city": "Tbilisi", "zip": "0159", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Teva Investigational Site 81040", "city": "Tbilisi", "zip": "0160", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Teva Investigational Site 81045", "city": "Tbilisi", "zip": "0171", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Teva Investigational Site 81042", "city": "Tbilisi", "zip": "0179", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Teva Investigational Site 81043", "city": "Tbilisi", "zip": "0186", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"facility": "Teva Investigational Site 51277", "city": "Budapest", "zip": "1083", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Teva Investigational Site 51278", "city": "Budapest", "zip": "1094", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Teva Investigational Site 51272", "city": "Budapest", "zip": "H-1021", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Teva Investigational Site 51279", "city": "Debrecen", "zip": "4032", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Teva Investigational Site 51271", "city": "Dombovar", "zip": "7200", "country": "Hungary", "geoPoint": {"lat": 46.37657, "lon": 18.13696}}, {"facility": "Teva Investigational Site 51269", "city": "Gyor", "zip": "9023", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"facility": "Teva Investigational Site 51274", "city": "Kaposvar", "zip": "7400", "country": "Hungary", "geoPoint": {"lat": 46.36667, "lon": 17.8}}, {"facility": "Teva Investigational Site 51270", "city": "Miskolc", "zip": "3526", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Teva Investigational Site 51276", "city": "Szeged", "zip": "6720", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Teva Investigational Site 51273", "city": "Szigetvar", "zip": "7900", "country": "Hungary", "geoPoint": {"lat": 46.04865, "lon": 17.80554}}, {"facility": "Teva Investigational Site 50444", "city": "Moscow", "zip": "125412", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Teva Investigational Site 50446", "city": "Perm", "zip": "614066", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "Teva Investigational Site 50445", "city": "Saint Petersburg", "zip": "196240", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 50443", "city": "Saint Petersburg", "zip": "196657", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 50442", "city": "Saint-Petersburg", "zip": "191144", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 50447", "city": "Saint-Petersburg", "zip": "192071", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 50441", "city": "Saint-Petersburg", "zip": "192148", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 50448", "city": "Saint-Petersburg", "zip": "196191", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Teva Investigational Site 50440", "city": "Tomsk", "zip": "634050", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Teva Investigational Site 58261", "city": "Chernivtsi", "zip": "58023", "country": "Ukraine", "geoPoint": {"lat": 48.29149, "lon": 25.94034}}, {"facility": "Teva Investigational Site 58262", "city": "Dnipropetrovsk", "zip": "49101", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Teva Investigational Site 58269", "city": "Ivano-Frankivsk", "zip": "76014", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Teva Investigational Site 58270", "city": "Kharkiv", "zip": "61093", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Teva Investigational Site 58265", "city": "Kryvyi Rih", "zip": "50082", "country": "Ukraine", "geoPoint": {"lat": 47.90966, "lon": 33.38044}}, {"facility": "Teva Investigational Site 58271", "city": "Kyiv", "zip": "03115", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Teva Investigational Site 58268", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Teva Investigational Site 58264", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Teva Investigational Site 58260", "city": "Lviv", "zip": "79059", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Teva Investigational Site 58259", "city": "Odesa", "zip": "65000", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Teva Investigational Site 58272", "city": "Odessa", "zip": "65000", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Teva Investigational Site 58263", "city": "Vinnytsya", "zip": "21021", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Teva Investigational Site 58267", "city": "Zaporizhzhia", "zip": "69063", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Teva Investigational Site 58266", "city": "Zaporizhzhya", "zip": "69038", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 841 participants with persistent asthma were randomized in a 1:1:1:1 ratio to receive Fp MDPI 25 mcg, Fp MDPI 50 mcg, FS MDPI 50/12.5 mcg, or placebo MDPI. Randomization was stratified by previous therapy (inhaled corticosteroid \\[ICS\\] or non-corticosteroid \\[NCS\\]).", "groups": [{"id": "FG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks."}, {"id": "FG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 micrograms (mcg) fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks."}, {"id": "FG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "FG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "209"}, {"groupId": "FG001", "numSubjects": "211"}, {"groupId": "FG002", "numSubjects": "210"}, {"groupId": "FG003", "numSubjects": "211"}]}, {"type": "Received at Least 1 Dose of Study Drug", "comment": "Safety analysis set", "achievements": [{"groupId": "FG000", "numSubjects": "209"}, {"groupId": "FG001", "numSubjects": "211"}, {"groupId": "FG002", "numSubjects": "208"}, {"groupId": "FG003", "numSubjects": "211"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "202"}, {"groupId": "FG001", "numSubjects": "206"}, {"groupId": "FG002", "numSubjects": "203"}, {"groupId": "FG003", "numSubjects": "205"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Other than specified", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by parent/guardian", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent-to-treat (ITT) analysis set included all randomized participants.", "groups": [{"id": "BG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "BG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "BG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "BG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "211"}, {"groupId": "BG002", "value": "210"}, {"groupId": "BG003", "value": "211"}, {"groupId": "BG004", "value": "841"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "211"}, {"groupId": "BG002", "value": "210"}, {"groupId": "BG003", "value": "211"}, {"groupId": "BG004", "value": "841"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.5", "spread": "1.98"}, {"groupId": "BG001", "value": "8.7", "spread": "1.83"}, {"groupId": "BG002", "value": "8.5", "spread": "1.94"}, {"groupId": "BG003", "value": "8.4", "spread": "2.05"}, {"groupId": "BG004", "value": "8.5", "spread": "1.95"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "211"}, {"groupId": "BG002", "value": "210"}, {"groupId": "BG003", "value": "211"}, {"groupId": "BG004", "value": "841"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "80"}, {"groupId": "BG003", "value": "91"}, {"groupId": "BG004", "value": "324"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "130"}, {"groupId": "BG001", "value": "137"}, {"groupId": "BG002", "value": "130"}, {"groupId": "BG003", "value": "120"}, {"groupId": "BG004", "value": "517"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "211"}, {"groupId": "BG002", "value": "210"}, {"groupId": "BG003", "value": "211"}, {"groupId": "BG004", "value": "841"}]}], "categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "172"}, {"groupId": "BG001", "value": "168"}, {"groupId": "BG002", "value": "171"}, {"groupId": "BG003", "value": "172"}, {"groupId": "BG004", "value": "683"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "32"}, {"groupId": "BG003", "value": "29"}, {"groupId": "BG004", "value": "135"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "6"}]}, {"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "3"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "13"}]}]}]}, {"title": "At-Home Baseline Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Baseline trough morning percent predicted FEV1 was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization.", "populationDescription": "Here, 'Number analyzed' signifies participants evaluable for this parameter.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent predicted of FEV1", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "211"}, {"groupId": "BG002", "value": "209"}, {"groupId": "BG003", "value": "211"}, {"groupId": "BG004", "value": "840"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "68.8", "spread": "9.70"}, {"groupId": "BG001", "value": "69.6", "spread": "9.68"}, {"groupId": "BG002", "value": "69.6", "spread": "9.47"}, {"groupId": "BG003", "value": "69.9", "spread": "9.15"}, {"groupId": "BG004", "value": "69.5", "spread": "9.49"}]}]}]}, {"title": "In-Clinic Baseline Percent Predicted FEV1", "description": "FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer. The baseline 1-hour trough morning percent predicted FEV1 was defined as the predose trough morning percent predicted FEV1 measurement at the randomization visit (Baseline \\[Day 1\\]) at the investigational center. 'Number of participants analyzed' for this parameter are 209, 211, 209, and 211 for each arm respectively.", "populationDescription": "Here, 'Number analyzed' signifies participants evaluable for this parameter.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent predicted of FEV1", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "211"}, {"groupId": "BG002", "value": "209"}, {"groupId": "BG003", "value": "211"}, {"groupId": "BG004", "value": "840"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "74.9", "spread": "14.58"}, {"groupId": "BG001", "value": "73.0", "spread": "13.43"}, {"groupId": "BG002", "value": "72.9", "spread": "13.00"}, {"groupId": "BG003", "value": "74.1", "spread": "15.02"}, {"groupId": "BG004", "value": "73.7", "spread": "14.03"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. The baseline 1-hour trough morning percent predicted FEV1 was defined as the predose trough morning percent predicted FEV1 measurement at the randomization visit (Baseline \\[Day 1\\]) at the investigational center. The IMP dose was administered right after the predose FEV1 measurement (within a 10 minute window). Participant then performed 1-hour (\u00b110 minutes) postdose lung function assessments on Week 12 at the investigational center.", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure. Missing data was imputed using MNAR methodology for prematurely discontinue participants or MAR for completers with implausible data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent predicted of FEV1", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "OG002", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "209"}, {"groupId": "OG002", "value": "211"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16.8", "spread": "1.32"}, {"groupId": "OG001", "value": "16.4", "spread": "1.32"}, {"groupId": "OG002", "value": "18.2", "spread": "1.29"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "groupDescription": "Analysis was performed using an ANCOVA model with effects due to baseline trough morning percent predicted FEV1, sex, age, (pooled) investigational center, previous therapy (ICS or NCS), and IMP treatment group.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.285", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "1.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.6", "ciUpperLimit": "5.3"}]}, {"type": "PRIMARY", "title": "For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Baseline trough morning percent predicted FEV1 was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \\[Day 1\\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \\[Day 1\\]). For postdose weekly average of trough morning percent predicted FEV1 measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning FEV1 values divided by the number of nonmissing assessments.", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure. Missing data was imputed using missing not at random (MNAR) methodology for prematurely discontinue participants or missing at random (MAR) for completers with implausible data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent predicted of FEV1", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "211"}, {"groupId": "OG002", "value": "209"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.3", "spread": "1.10"}, {"groupId": "OG001", "value": "13.3", "spread": "1.09"}, {"groupId": "OG002", "value": "14.2", "spread": "1.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using an analysis of covariance (ANCOVA) model with effects due to baseline trough morning percent predicted FEV1, sex, age, (pooled) investigational center, previous therapy (inhaled corticosteroid \\[ICS\\] or noncorticosteroid \\[NCS\\]), and investigational medicinal product (IMP) treatment group.", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "ANCOVA", "paramType": "Least square (LS) mean difference", "paramValue": "6.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.2", "ciUpperLimit": "8.8"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Analysis was performed using an ANCOVA model with effects due to baseline trough morning percent predicted FEV1, sex, age, (pooled) investigational center, previous therapy (ICS or NCS), and IMP treatment group.", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "7.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.1", "ciUpperLimit": "9.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period", "description": "PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Morning PEF was determined in the morning, before administration of IMP or rescue medications. Baseline trough morning PEF was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline \\[Day 1\\]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline \\[Day 1\\]). For postdose weekly average of trough morning PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning PEF values divided by the number of nonmissing assessments.", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters/minute", "timeFrame": "Baseline, Week 1 to 12", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "OG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "210"}, {"groupId": "OG002", "value": "208"}, {"groupId": "OG003", "value": "211"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.3", "spread": "2.65"}, {"groupId": "OG001", "value": "28.9", "spread": "2.62"}, {"groupId": "OG002", "value": "26.3", "spread": "2.64"}, {"groupId": "OG003", "value": "32.0", "spread": "2.61"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12", "description": "Participants recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each morning and evening in the electronic patient diary. An entry of 0 inhalations indicated no rescue medication was needed. To calculate the total daily use of albuterol/salbutamol inhalation aerosol (number of inhalations), the electronic patient diary entry on randomization visit (Baseline \\[Day 1\\]) was defined as the first day of analysis. The weekly average of the total daily inhalations was the average based on the available data for that week. The average was calculated as the sum of total daily inhalations over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and standard error (SE) were obtained using mixed model for repeated measures (MMRM).", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "inhalations", "timeFrame": "Baseline, Week 1 to 12", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "OG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "210"}, {"groupId": "OG002", "value": "209"}, {"groupId": "OG003", "value": "211"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.4", "spread": "0.05"}, {"groupId": "OG002", "value": "-0.5", "spread": "0.05"}, {"groupId": "OG003", "value": "-0.4", "spread": "0.05"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12", "description": "Asthma symptom scores were recorded in the patient diary. Each participant assessed the symptoms of cough, wheeze, shortness of breath, and chest tightness and entered a single score that was inclusive of all symptoms. Daytime Symptom Score (determined in the evening) ranged from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. Nighttime Symptom Score (determined in the morning) ranged from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score was the average of the daytime and nighttime scores. The total daily asthma symptom score ranged from 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night. The weekly average was calculated as the sum of total daily asthma symptom scores over the 7 days for each analysis week divided by the number of nonmissing assessments. LS mean and SE were obtained using MMRM.", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 1 to 12", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "OG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "210"}, {"groupId": "OG002", "value": "209"}, {"groupId": "OG003", "value": "211"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.02"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.02"}, {"groupId": "OG002", "value": "-0.2", "spread": "0.02"}, {"groupId": "OG003", "value": "-0.2", "spread": "0.02"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period", "description": "C-ACT was a simple, participant-completed tool used for the assessment of overall asthma control. The first 4 items of the test were completed by the participant, while the last 3 items were completed by the participant's parents/legal guardians/caregivers. A total sum score based upon responses to all items was calculated to provide an overall measure of asthma control. The derived C-ACT score ranging from 0 to 27. These scores spanned the continuum of poor control of asthma (score \u22645) to complete control of asthma (score \u226525), with a cut off score of 19 indicating participants with poorly controlled asthma. LS mean and SE were obtained using MMRM.", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Week 1 to 12", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "OG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "208"}, {"groupId": "OG002", "value": "205"}, {"groupId": "OG003", "value": "209"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "0.21"}, {"groupId": "OG001", "value": "5.1", "spread": "0.21"}, {"groupId": "OG002", "value": "5.5", "spread": "0.21"}, {"groupId": "OG003", "value": "5.4", "spread": "0.21"}]}]}]}, {"type": "SECONDARY", "title": "Time to First Onset of Effect", "description": "The time to first onset of effect, defined as the first decrease from baseline in daily rescue medication use, was calculated based on the number of inhalations of rescue medication (albuterol/salbutamol hydrofluoroalkane metered-dose inhaler \\[HFA MDI\\] \\[90 mcg ex actuator\\] or equivalent) recorded by the participant each morning and evening in the patient diary built into the handheld device.", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "days", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "OG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "210"}, {"groupId": "OG002", "value": "208"}, {"groupId": "OG003", "value": "211"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.0", "lowerLimit": "5.0", "upperLimit": "NA", "comment": "Due to smaller number of participants with an event, upper limit of 95% confidence interval (CI) could not be calculated."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "3.0", "upperLimit": "NA", "comment": "Due to smaller number of participants with an event, median and upper limit of 95% CI could not be calculated."}, {"groupId": "OG002", "value": "2.0", "lowerLimit": "2.0", "upperLimit": "2.0"}, {"groupId": "OG003", "value": "6.0", "lowerLimit": "2.0", "upperLimit": "NA", "comment": "Due to smaller number of participants with an event, upper limit of 95% CI could not be calculated."}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period", "populationDescription": "ITT analysis set included all randomized participants. Here, 'Overall number of participants analyzed' signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline up to Week 12", "groups": [{"id": "OG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks."}, {"id": "OG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks."}, {"id": "OG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks."}, {"id": "OG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "210"}, {"groupId": "OG002", "value": "208"}, {"groupId": "OG003", "value": "211"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline up to Week 13", "description": "Safety analysis set included all randomized participants who received at least 1 dose of IMP.", "eventGroups": [{"id": "EG000", "title": "Placebo MDPI", "description": "Participants received matching placebo via MDPI for 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 209, "seriousNumAffected": 1, "seriousNumAtRisk": 209, "otherNumAffected": 11, "otherNumAtRisk": 209}, {"id": "EG001", "title": "Fp MDPI 25 mcg BID", "description": "Participants received 1 inhalation of 25 mcg fluticasone propionate via MDPI BID (total daily dose: 50 mcg) for 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 211, "seriousNumAffected": 2, "seriousNumAtRisk": 211, "otherNumAffected": 8, "otherNumAtRisk": 211}, {"id": "EG002", "title": "Fp MDPI 50 mcg BID", "description": "Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 208, "seriousNumAffected": 1, "seriousNumAtRisk": 208, "otherNumAffected": 11, "otherNumAtRisk": 208}, {"id": "EG003", "title": "FS MDPI 50/12.5 mcg BID", "description": "Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 211, "seriousNumAffected": 4, "seriousNumAtRisk": 211, "otherNumAffected": 9, "otherNumAtRisk": 211}], "seriousEvents": [{"term": "Lymphadenitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 211}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 211}]}, {"term": "Pneumonia mycoplasmal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 211}]}, {"term": "Partial seizures", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 211}]}, {"term": "Disruptive mood dysregulation disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 211}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 11, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 211}, {"groupId": "EG002", "numEvents": 11, "numAffected": 11, "numAtRisk": 208}, {"groupId": "EG003", "numEvents": 9, "numAffected": 9, "numAtRisk": 211}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc.", "email": "USMedInfo@tevapharm.com", "phone": "1-888-483-8279"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-06-05", "uploadDate": "2020-03-05T11:26", "filename": "Prot_000.pdf", "size": 4803252}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-04-16", "uploadDate": "2020-03-05T11:26", "filename": "SAP_001.pdf", "size": 891244}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Poland"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}